Exenatide once weekly improved glycaemic control cardiometabolic risk factors and a composite index of an HbA1c 7 without weight gain or hypoglycaemia over 52 weeks

摘要

AimsType 2 diabetes mellitus (T2DM) is often associated with cardiovascular (CV) risk factors such as obesity, hypertension and dyslipidemia. The objective of this analysis was to evaluate potential effects of exenatide once weekly (ExQW), a GLP-1 receptor agonist, on glycaemic control and CV risk factors.